Original research on why launches beat or miss their forecast, scenario work on the market they will launch into, and shorter pieces on what is changing and what it means for a launch team.

198 FDA approvals read through their DNA. Eleven traits, most of them fixed before approval, separate launches that tend to beat their forecast from launches that tend to miss.
Read the research →
Four plausible futures for the U.S. launch environment, and what each one changes about turning a medicine into a viable business.
Read the report →New pieces by email: subscribe to the newsletter. Or follow the RSS feed.
If your organization is launching a new therapy where failure is not an option, let’s talk.
Start a conversation